Enanta Pharma

ENTA NASDAQ
92.14
-1.30
-1.39%
After Hours: 92.14 0 0.00% 16:58 05/23 EDT
Open
92.71
Prev Close
93.44
High
92.85
Low
89.15
Volume
167.08K
Avg Vol (3M)
198.23K
52 Week High
127.77
52 Week Low
64.09
% Turnover
0.85%
Market Cap
1.81B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Enanta Pharma ENTA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
MORE >

Recently

Name
Price
%Change